Ikena Oncology Return on Investment 2021-2025 | IMA
Current and historical return on investment (ROI) values for Ikena Oncology (IMA) over the last 10 years.
| Ikena Oncology ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2025-03-31 |
$-0.05B |
|
0.00% |
| 2024-12-31 |
$-0.06B |
|
0.00% |
| 2024-09-30 |
$-0.07B |
|
0.00% |
| 2024-06-30 |
$-0.08B |
|
0.00% |
| 2024-03-31 |
$-0.08B |
|
0.00% |
| 2023-12-31 |
$-0.08B |
|
0.00% |
| 2023-09-30 |
$-0.07B |
|
0.00% |
| 2023-06-30 |
$-0.07B |
|
0.00% |
| 2023-03-31 |
$-0.07B |
|
0.00% |
| 2022-12-31 |
$-0.07B |
|
0.00% |
| 2022-09-30 |
$-0.05B |
|
0.00% |
| 2022-06-30 |
$-0.05B |
|
0.00% |
| 2022-03-31 |
$-0.04B |
|
0.00% |
| 2021-12-31 |
$-0.04B |
|
0.00% |
| 2021-09-30 |
$-0.07B |
|
0.00% |
| 2021-06-30 |
$-0.06B |
|
0.00% |
| 2021-03-31 |
$-0.06B |
|
0.00% |
| 2020-12-31 |
$-0.05B |
|
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.061B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
